Angiotech Pharmaceuticals Inc., of Vancouver, British Columbia, appointed Thomas Bailey vice president of business development.
Auxeris Therapeutics Inc., of St. Louis, appointed William Boyle chief scientific officer.
Basilea Pharmaceutica, of Basel, Switzerland, appointed Rienk Pypstra chief development officer.
Benitec, of Queensland, Australia, appointed Sally Brashears vice president, IP. The company also expanded its scientific advisory board to include Mark Kay as deputy chairman and Jo Milner, Robert Lanford and David Russell as members.
Beyond Genomics Inc., of Waltham, Mass., appointed Stephen Martin senior vice president and chief technical officer.
BioLineRx, of Jerusalem, appointed Kinneret Savitsky vice president of drug development.
Biotechnology Industry Organization, of Washington, appointed Sean Darragh executive director of the food and agriculture section.
Cellomics Inc., of Pittsburgh, appointed William Sharp vice president of business development.
Codexis, of Redwood City, Calif., appointed David Walshaw head of production planning and supply chain management.
Corixa Corp., of Seattle, appointed Christof Marre vice president of marketing.
Erxsys Inc., of Irvine, Calif., appointed James Manfredonia to its board.
Exagen Diagnostics, of Albuquerque, N.M., appointed Suzanne Mattingly vice president of business development and marketing.
Eyetech Pharmaceuticals Inc., appointed Michael Regan and Phillip Satow to its board.
Genelabs Technologies Inc., of Redwood City, Calif., appointed Adrian Arima vice president and general counsel.
GeneMax Corp., of Vancouver, British Columbia, appointed Edward Farrauto chief financial officer, treasurer and secretary.
Genencor International Inc., of Palo Alto, Calif., appointed Margaret Horn general counsel and secretary of its board.
Gentris Corp., of Research Triangle Park, N.C., promoted Dawn Bordeaux to vice president of regulatory affairs and quality assurance.
GenVault, of San Diego, appointed Jay Flatley and Jim Schlater to its board.
HepaLife Technologies Inc., of Vancouver, British Columbia, appointed Frank Menzler and John Bergmannto to its scientific advisory board.
Hollis-Eden Pharmaceuticals Inc., of San Diego, named Jessie Groothuis vice president of clinical affairs.
Icagen Inc., of Research Triangle Park, N.C., appointed Mark Suto vice president of chemistry.
Igeneon AG, of Vienna, Austria, appointed Manfred Ruediger CEO.
ImClone Systems Inc., of New York, named Michael Howerton senior vice president and chief financial officer.
Invitrogen Corp., of Carlsbad, Calif., appointed Craig Mello a scientific adviser.
Lexicon Genetics Inc., of The Woodlands, Texas, appointed Gregory Landes vice president of biotherapeutics.
MediciNova Inc., of San Diego, appointed Brian Anderson executive vice president of corporate development.
NanoBio, of Ann Arbor, Mich., appointed Jay Birnbaum to its science advisory board.
Neoprobe Corp., of Dublin, Ohio, appointed Carl Aschinger to its board.
NeoStem, of Agoura Hills, Calif., appointed Richard Gatti to its medical advisory board.
Neurocrine Biosciences Inc., of San Diego, elected Corinne Lyle to its board.
NovaDel Pharma Inc., of Flemington, N.J., appointed Chairman Charles Nemeroff and members Lindsay DeVane, Ranga Rama Krishnan, Allan Levey and Stephen Stahl to its scientific advisory board.
Novo Nordisk, of Princeton, N.J., appointed Jeff Frazier vice president of human resources.
Onyx Pharmaceuticals Inc., of Richmond, Calif., appointed Edward Kenney executive vice president and chief business officer.
OXIS International Inc., of Portland, Ore., appointed Gosse Bruinsma chairman and acting CEO.
Pacific Growth Equities, of San Francisco, promoted Liana Moussatos to senior biotechnology/biopharmaceutical analyst.
Paradigm Genetics Inc., of Research Triangle Park, N.C., appointed Peter Tombros to its board.
Penwest Pharmaceuticals Co., of Danbury, Conn., appointed Alan Joslyn senior vice president of research and development.
Perlegen Sciences Inc., of Mountain View, Calif., appointed Russell Singleton vice president of engineering and informatics, and William Sims chief financial officer.
Pharsight Corp., of Mountain View, Calif., appointed Daniel Weiner senior vice president of business development.
Piper Jaffray & Co., of New York, appointed Ryan Steward managing director and senior research analyst.
Piramed Ltd., of Slough, UK, appointed Ian Kent nonexecutive chairman and Frank Fildes nonexecutive director of its board.
Prolexys Pharmaceuticals Inc., of Salt Lake City, appointed Kimberly Rogers vice president of business development.
Protein Design Labs Inc., of Fremont, Calif., named Richard Murray senior vice president and chief scientific officer.
Protein Polymer Technologies Inc., of San Diego, appointed Donald Kaplan, Steven Lamon and Steve Peltzman, and re-elected Edward Cape, Kerry Kuhn, Thomas Parmeter and George Walker, to its board.
RegeneRx Biopharmaceuticals Inc., of Bethesda, Md., appointed Mauro Bove to its board.